Loading
RNA Interference and Gene Delivery / CRISPR and Genetic Engineering · Journal article
Idosr Journal of Applied Sciences · September 8, 2026
Raises a question worth testing. It does not answer one.
This narrative review synthesizes the preclinical rationale and current evidence for CRISPR-Cas13-based RNA targeting of HIV reservoirs as a path toward functional remission. While mechanistic proof-of-concept studies show Cas13 can reduce HIV RNA levels and blunt viral gene expression in vitro or in animal models, durable impacts on reservoir size and clinical remission in humans remain undemonstrated, and substantial barriers in delivery, off-target effects, immune recognition, and safety optimization must be resolved before clinical translation.
Narrative review. Peer-reviewed literature on CRISPR-Cas13 RNA-targeting and HIV reservoir dynamics; no human study population.. Intervention: CRISPR-Cas13 RNA-guided nuclease (type VI) for programmable targeting and degradation of HIV RNA transcripts..
40.8 million people living with HIV as of 2024 require lifelong combination antiretroviral therapy due to persistent replication-competent provirus and low-level transcription in reservoir tissues. Cas13-based constructs can efficiently reduce HIV RNA levels and blunt viral gene expression in proof-of-concept studies. Key limitations include delivery barriers to reservoir-rich tissues, off-target and collateral RNA cleavage, immune recognition, and scalability in diverse patient populations.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and researchers should regard CRISPR-Cas13 as a scientifically compelling preclinical concept with potential to shift HIV management from lifelong suppression to functional remission, but current evidence is insufficient to guide clinical decision-making. Substantial work on vector design, tissue delivery, and long-term safety is required before clinical trials are realistic.
A narrative review of preclinical and mechanistic studies proposing CRISPR-Cas13 as a therapeutic concept for HIV remission, without clinical trial data or definitive evidence of durable clinical benefit.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and researchers should regard CRISPR-Cas13 as a scientifically compelling preclinical concept with potential to shift HIV management from lifelong suppression to functional remission, but current evidence is insufficient to guide clinical decision-making. Substantial work on vector design, tissue delivery, and long-term safety is required before clinical trials are realistic.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Human immunodeficiency virus (HIV) persisted as a significant global health burden, with an estimated 40.8 million people living with HIV as of 2024 despite widespread access to combination antiretroviral therapy (cART). Lifelong therapy was still required because replication-competent provirus and low-level viral transcription persisted in long-lived reservoir-containing tissues, including lymphoid organs, gut-associated lymphoid tissue, and central nervous system niches. CRISPR-Cas13, a type VI RNA-guided nuclease, has emerged as a versatile platform for programmable RNA targeting, offering the possibility of selectively degrading HIV RNA transcripts while sparing the host genome. This narrative review examined CRISPR-Cas13 RNA-targeting therapeutics in the context of achieving functional HIV remission, synthesizing current knowledge on Cas13 biology, HIV reservoir dynamics, proof-of-concept studies, and translational delivery strategies to reservoir-rich tissues. A narrative review methodology was employed, drawing on peer-reviewed literature from PubMed, Scopus, and major publishers between 2015 and 2026, with emphasis on mechanistic and preclinical studies. Emerging findings indicated that Cas13-based constructs can efficiently reduce HIV RNA levels and blunt viral gene expression, though durable impacts on reservoir size and clinical remission remain to be demonstrated. Key limitations included delivery barriers, off-target and collateral RNA cleavage, immune recognition, and scalability in diverse patient populations. CRISPR-Cas13 RNA-targeting therapeutics represented a scientifically compelling avenue for shifting HIV management from lifelong suppression to functional remission, but substantial optimization of vector design, delivery to tissue reservoirs, and long-term safety is still required before clinical translation is realistic. Keywords: CRISPR-Cas13, RNA targeting, HIV reservoirs, Functional remission, Gene therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.